How to Help Your Patients Find Serevent in Stock: A Provider's Guide

When a patient reports they can't fill their Serevent Diskus (salmeterol) prescription, the problem is usually not a national supply shortage — it's a combination of pharmacy-level stocking inconsistencies, insurance barriers, and high out-of-pocket costs. This guide outlines specific, actionable tools you can use or recommend to help your patients access Serevent reliably.

Step 1: Diagnose the Access Problem

Before recommending a solution, identify which barrier your patient is facing:

Pharmacy stock gap: Their pharmacy simply doesn't have it in stock right now. Solution: find another pharmacy.

Insurance denial or prior auth: Prescription is written but insurance won't cover it or requires PA. Solution: PA submission or formulary appeal.

Cost barrier: Patient can't afford even with insurance (high copay) or has no insurance. Solution: manufacturer savings programs or patient assistance.

All of the above: Some patients face multiple layers. A combination of strategies is needed.

For Pharmacy Stock Gaps: Refer Patients to medfinder

When patients can't find Serevent at their usual pharmacy, the most efficient tool is medfinder for Providers. Patients submit their medication, dosage, and zip code; medfinder calls pharmacies in their area and identifies which ones can fill the prescription. Results are texted to the patient.

This is especially useful for Serevent because it's a specialty inhaler that some pharmacies only stock on-demand. Availability varies significantly by geographic area and by individual pharmacy ordering patterns.

For Insurance Denials: Prior Authorization Strategies

Serevent is commonly denied for "therapeutic alternative available" when insurance plans consider combination ICS/LABA inhalers as equivalent. To support a prior authorization for standalone salmeterol, include documentation of:

Why individualized ICS and LABA dosing is clinically necessary (if applicable)

Specific ICS regimen already in use that lacks a salmeterol combination product

History of adverse reaction, inadequate response, or device intolerance to combination alternatives

For COPD: clinical preference for standalone LABA without ICS to avoid pneumonia risk in susceptible patients

For Cost Barriers: GSK Patient Programs

GSK offers two key programs for Serevent Diskus:

GSK 'Pay No More Than $35' Coupon: Available at gskforyou.com for commercially insured patients (excluding government-insured patients on Medicare, Medicaid, TRICARE). Patients use the coupon at participating pharmacies to cap their monthly out-of-pocket to $35.

GSK Access Patient Assistance Program: For uninsured or underinsured patients who meet income requirements. Your office can help patients complete the application (available on gsk-access.com or by calling 1-866-728-4368). Approved patients receive Serevent Diskus at no cost.

For Medicare Patients

Medicare Part D coverage of Serevent varies significantly by plan. Key points to communicate to Medicare patients:

Medicare patients are NOT eligible for the GSK $35 commercial coupon

Medicare patients who qualify based on income may be eligible for the GSK Access Patient Assistance Program

The Medicare Part D OOP cap is $2,100 in 2026 — Serevent may count toward this cap

Low-income subsidy (LIS/Extra Help) may reduce costs for eligible patients to near zero

When to Consider an Alternative

If a patient continues to face persistent access barriers and a combination ICS/LABA would be clinically appropriate, consider switching. For asthma patients, Wixela Inhub (generic fluticasone/salmeterol) contains the same LABA as Serevent. Generic budesonide/formoterol (Symbicort generic) is typically the most cost-accessible option with broad formulary coverage.

For a full clinical briefing on the shortage context and alternative options, see: Serevent Shortage: What Providers Need to Know in 2026.